1
|
Pan F, Chen Y, He JZ, Long L, Chen Y, Luo HJ, Xu YW, Pang XX, Yang Q, Wang JJ, Xu XE, Wang SH, Li EM, Xu LY. Dietary riboflavin deficiency promotes N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in rats by inducing chronic inflammation. Am J Cancer Res 2019; 9:2469-2481. [PMID: 31815047 PMCID: PMC6895446 DOI: pmid/31815047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 10/18/2019] [Indexed: 02/05/2023] Open
Abstract
Epidemiological studies in high-incidence areas of esophageal cancer in China suggest that environmental carcinogen N-nitrosomethylbenzylamine (NMBA) and riboflavin (RBF) deficiency may be the main risk factors for esophageal cancer. However, it is not clear that the combination induces cancer. Here, experiment (Exp) 1 evaluated the effects of NMBA and RBF deficiency individually or in combination on esophageal tumorigenesis. Male F344 rats were randomly assigned to 4 groups into a 2 (no NMBA vs. NMBA) × 2 (normal RBF vs. RBF-deficient) factorial design, including normal RBF (6 mg/kg, R6), RBF-deficient (0 mg/kg, R0), normal RBF combined with NMBA (R6N), and RBF-deficient combined with NMBA (R0N) groups. The Exp 2 explored the effects of RBF deficiency at different doses combined with NMBA (0.6 mg/kg, R0.6N; 0.06 mg/kg, R0.06N) on esophageal tumorigenesis. Results showed that R0N enhanced the incidence of esophageal intraepithelial neoplasia (EIN, 53.3%, P = 0.06), including carcinoma in situ, whereas R6N mainly induced the occurrence of esophageal benign hyperplasia (38.9%) and EIN (16.7%). RBF deficiency promotes EIN in a dose-dependent manner, and R0.06N significantly increases the incidence of EIN (57.9%, P < 0.05). Gene expression profiling demonstrated that inflammatory cytokines were highly expressed in R0N EIN tissues, whereas R6N EIN tissues had a proliferation and differentiation gene signature (fold-change > 1.5). Furthermore, RBF deficiency aggravated oxidative DNA damage (8-OHdG) and double-strand breaks (γH2AX) (P < 0.05). Our results suggest that RBF deficiency causes chronic inflammation-associated genomic instability contributes to NMBA-induced esophageal tumorigenesis.
Collapse
Affiliation(s)
- Feng Pan
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Department of Biochemistry and Molecular Biology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Ye Chen
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Institute of Oncologic Pathology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Jian-Zhong He
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Institute of Oncologic Pathology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Lin Long
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Department of Biochemistry and Molecular Biology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Yang Chen
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Department of Biochemistry and Molecular Biology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Hong-Jun Luo
- Bioanalytical Laboratory, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Yi-Wei Xu
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Department of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical CollegeShantou 515041, Guangdong, China
| | - Xiao-Xiao Pang
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Institute of Oncologic Pathology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Qian Yang
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Institute of Oncologic Pathology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Juan-Juan Wang
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Institute of Oncologic Pathology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Xiu-E Xu
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Institute of Oncologic Pathology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Shao-Hong Wang
- Department of Pathology, Shantou Central Hospital, Affiliated Shantou Hospital of Sun Yat-sen UniversityShantou 515041, Guangdong, China
| | - En-Min Li
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Department of Biochemistry and Molecular Biology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| | - Li-Yan Xu
- Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Medical College of Shantou UniversityShantou 515041, Guangdong, China
- Institute of Oncologic Pathology, Medical College of Shantou UniversityShantou 515041, Guangdong, China
| |
Collapse
|
2
|
Deng J, Zhang J, Wang C, Wei Q, Zhou D, Zhao K. Methylation and expression of PTPN22 in esophageal squamous cell carcinoma. Oncotarget 2018; 7:64043-64052. [PMID: 27613842 PMCID: PMC5325424 DOI: 10.18632/oncotarget.11581] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 08/17/2016] [Indexed: 12/18/2022] Open
Abstract
Esophageal squamous cell carcinoma (ESCC) is a fatal disease contributed by both genetic and epigenetic factors. The epigenetic alteration of protein tyrosine phosphatase non-receptor type 22 (PTPN22) and its clinical significance in ESCC were still not yet clarified. A quantitative methylation study of PTPN22 and its expression were conducted in 121 and 31 paired tumor and adjacent normal tissue (ANT), respectively. Moreover, the association between PTPN22 methylation and clinicopathological parameters was evaluated. We found that the methylation level of PTPN22 was significantly elevated in tumor tissues (66.3%) relative to ANT (62.1%) (p=0.005). The methylation level of non-smoking ANT (59.1%) was significant lower than smoking ESCC tissue (65.8%) (p=0.03); similarly, the methylation levels in ANT with no lymph node invasion (57.6%) were significant lower than tumor tissues with lymph node invasion (67.5%) (p=0.001). PTPN22 expression in ESCC was lower than normal tissues, however the difference was not statistically significant (p=0.55). Lower expression was more frequently occurred in N1-3 and III stage patients, while higher expression was more likely to occur in N0 and I-II stage patients. Lower expression of PTPN22 was associated with poor overall survival (p=0.04). Taken together, PTPN22 was hypermethylationed in ESCC. Hypermethylation was associated with lymph node invasion. The PTPN22 expression may act as a prognostic biomarker to identify patients at risk of high grade.
Collapse
Affiliation(s)
- Jiaying Deng
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Junhua Zhang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Chunyu Wang
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Qing Wei
- Department of Pathology, Tenth People's Hospital of Tongji University, Shanghai 200072, China
| | - Daizhan Zhou
- Bio-X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China
| | - Kuaile Zhao
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
| |
Collapse
|